診療科・部門紹介

TR支援部（先進がん治療開発センター）

最終更新日 : 2024年8月14日

⇒　「先進がん治療開発センターについて」に戻る

TR支援部のご紹介

渡邊　雅之　部長
渡邊　雅之　部長

病院3階の一区画に臨床医のための開かれた実験スペース（オープンラボ）が設置されており、研究に興味があるがん研有明病院の臨床医の先生方にご利用いただいています。年１回の研究進捗報告会及び新規研究検討会を年１回開催しています。　

研究に興味のあるがん研有明病院の先生方はどなたでもご相談下さい。　　　　　　

以下に、オープンラボを利用された研究者の論文をご紹介いたします。

オープンラボを利用された研究者の英文論文業績

  1. Bao C, Watanabe M, Imamura Y, et al: Genomic signatures of past and present chromosomal instability in Barrett’s esophagus and early esophageal adenocarcinoma. Nat Commun 14(1):6203, 2023
  2. Shimozaki K, Imamura Y, Watanabe M, et al: KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. J Cancer Res Clin Oncol 149(3):1273-1283, 2023
  3. Akiyoshi T, et al: Transcriptomic Analyses Reveal Pre-treatment Cytotoxic Lymphocytes Predict Response to Neoadjuvant Chemoradiotherapy and Survival in Advanced Rectal Cancer. JAMA Netw Open 6(1):e2252140, 2023
  4. Sano S, Akiyoshi T, et al: Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer. Clin Colorectal Cancer S1533-0028(23)00063-4, 2023
  5. Zhang CD, Imamura Y, Watanabe M, et al: Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation. Gastric Cancer 25:336-345, 2022
  6. Akiyoshi T, et al: Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial). BMJ Open 12(3):e055140, 2022
  7. Kitagawa Y, Akiyoshi T, et al: Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer. Clin Colorectal Cancer 21(1):e1-e11,2022
  8. Imamura Y, Watanabe M, et al: Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann Gastroenterolo Surg 5:46-59, 2021
  9. Imamura Y, Noda T, Watanabe M: Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses. Int J Cancer 148:1260-1275, 2021
  10. Kobayashi K, Yamaguchi K, et al: Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 olymorphisms in patients with metastatic colorectal cancers. Cancer Chemotherapy and Pharmology 87(6):767-777, 2021
  11. Akiyoshi T, et al: T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer. Cancer Immunol Immunother 70(2):509-518, 2021
  12. Sawada R, Akiyoshi T, et al: Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer. Ann Surg Oncol 28(11):6189-6198, 2021
  13. Murahashi S, Akiyoshi T, et al: Serial circulating tumor DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer 123(5):803-810, 2020
  14. Nakanishi R, Akiyoshi T, et al. Radiomics Approach Outperforms Diameter Criteria for Predicting Pathological Lateral Lymph Node Metastasis After Neoadjuvant (Chemo)Radiotherapy in Advanced Low Rectal Cancer. Ann Surg Oncol 27(11):4273-4283, 2020
  15. Fennell L, Imamura Y, et al: Integrative genome-scale DNA Methylation analysis of a large and unselected cohort reveals five distinct subtypes of Colorectal Adenocarcinomas. Cell Mol Gastroenterol Hepatol 8(2):269-290, 2019
  16. Imamura Y, Watanabe M, et al: Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma, and microsatellite instability status in Japanese patients. Digestion 99(1):6-13, 2019
  17. Tominaga T, Akiyoshi T, et al: Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS One 14(2):e0212978, 2019
  18. Akiyoshi T, et al: Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg 106(10):1381-1392, 2019
  19. Tominaga T, Akiyoshi T, et al: Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Surgery 166(6):1061-1067, 2019
  20. Yagi S, Wakatsuki T, et al: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer 22(3):518-525, 2019
  21. Bahcall M, Watanabe M, Imamura Y, et al: Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer. Clin Cancer Res 24(23):5963-5976, 2018
  22. Cañadas I, Imamura Y, Watanabe M, et al: Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24(8):1143-1150, 2018
  23. Wong GS, Watanabe M, Imamura Y, et al: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24(7):968-977, 2018
  24. Pectasides E, Watanabe M, Imamura Y, et al: Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8(1):37-48, 2018
  25. Ogura A, Akiyoshi T, et al: Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. Eur J Cancer 91:11-20, 2018
  26. Wakatsuki T, et al: Clinical Impact of Intratumoral HER2 Heterogeneity on Trastuzumab Efficacy in Patients with HER2 Positive Gastric Cancer. J Gastroenterol 53(11):1186-95, 2018

 

 

このページのTOPへ